title: Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats.
abstract: Troleandomycin (TAO), a selective family 3A cytochromes P450 (CYP3A) inhibitor, decreases enhanced in vivo corticosterone 6 beta-hydroxylation and blood pressure in spontaneously hypertensive rats (SHR). Corticosterone 6 beta-hydroxylation was measured in liver and kidney microsomes, to determine ontogeny and the effect of TAO on CYP3A activity at the organ level. SHR kidney CYP3A activity increased from 4 to 8 weeks, stabilized at 11 and 16 weeks, and was much higher than in control (Wistar-Kyoto, WKY) rats at all ages. Hepatic activity showed less consistency in strain difference. TAO produced a relatively large decrease in renal CYP3A activity compared with liver. Although renal CYP3A mRNA was not present in sufficient quantity for detection by northern blot analysis of total RNA, its presence was demonstrated in SHR by reverse transcriptase-polymerase chain reaction amplification. Correlations between renal CYP3A activity and systolic blood pressure in SHR and WKY rats with variations in age, strain and drug treatment are consistent with the role of the enzyme in the pathogenesis of blood pressure elevation in SHR.
authors.affiliation: Department of Medicine, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298, USA.
authors.forename: S S
authors.initials: SS
authors.lastname: Ghosh
authors.forename: A K
authors.initials: AK
authors.lastname: Basu
authors.forename: S
authors.initials: S
authors.lastname: Ghosh
authors.forename: R
authors.initials: R
authors.lastname: Hagley
authors.forename: L
authors.initials: L
authors.lastname: Kramer
authors.forename: J
authors.initials: J
authors.lastname: Schuetz
authors.forename: W M
authors.initials: WM
authors.lastname: Grogan
authors.forename: P
authors.initials: P
authors.lastname: Guzelian
authors.forename: C O
authors.initials: CO
authors.lastname: Watlington
mesh_terms: D000818:Animals; D001483:Base Sequence; D019392:Cytochrome P-450 CYP2E1; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D017931:DNA Primers; D006973:Hypertension / Q000201:enzymology*; D007668:Kidney / Q000201:enzymology*; D008099:Liver / Q000201:enzymology*; D008297:Male; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D014217:Troleandomycin / Q000494:pharmacology
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D017931:DNA Primers; D012333:RNA, Messenger; D003577:Cytochrome P-450 Enzyme System; D014217:Troleandomycin; D006899:Mixed Function Oxygenases; D019392:Cytochrome P-450 CYP2E1